You are here: Industry Insights > GlymaxX

News List

Another Clinical Asset Using ProBioGen's GlymaxX® Technology Begins Phase III PharmaSources
January 26, 2023
ProBioGen today announced that a Novartis clinical candidate using its antibody-dependent cellular cytotoxicity (ADCC) technology, GlymaxX, has reached Phase III.
ProBioGen Signs a Commercial License Agreement with AstraZeneca Providing their GlymaxX® Technology b3cnewswire
February 11, 2022
ProBioGen announces a multi-product commercial license agreement with AstraZeneca to use the GlymaxX technology.
ProBioGen Announces Innovent as a New Partner Signing License of GlymaxX® Technology B3Cnewswire
January 14, 2022
ProBioGen today announced that Innovent Biologics, Inc. (1801.HK) has signed a multi-product license for ProBioGen's GlymaxX technology.
ProBioGen's GlymaxX® Technology Reaches Phase III Clinical Development B3Cnewswire
December 20, 2021
ProBioGen, a leading technology developer and CDMO for cell line development through GMP manufacturing announces an important clinical milestone for its GlymaxX antibody-dependent cellular cytotoxicity (ADCC) enhancement technology.
ProBioGen’s GlymaxX Technology Reaches Phase III Development contractpharma
December 17, 2021
Zymeworks recently announced a global Phase III clinical trial of zanidatamab in HER2‑expressing gastroesophageal cancer.
ProBioGen's GlymaxX® Technology Made It Again into Clinical Phase I B3Cnewswire
November 18, 2021
ProBioGen, a premier CDMO for cell line development through GMP manufacturing which has also developed innovative technologies, announced that another product candidate applying its antibody-dependent cellular cytotoxicity...
AbbVie Licenses ProBioGen’s GlymaxX Technology contractpharma
January 26, 2021
ProBioGen has signed a commercial license agreement with AbbVie to apply ProBioGen's GlymaxX technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC).
ProBioGen Licenses GlymaxX® Technology to Bayer b3cnewswire
September 17, 2019
ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, announced the closing of a license agreement with Bayer AG for the GlymaxX® Technology.
ProBioGen, Abcuro Ink GlymaxX Pact contractpharma
May 29, 2019
ProBioGen to provide cell line development leveraging its CHO.RiGHT expression platform through to GMP production.